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Normal human B  cell proliferation is a  multistep process,  involving cellular 
activation by antigen through antigen-specific cell surface immunoglobulin re- 
ceptors (sIg) (1), followed by mitogenic stimulation by the lineage-specific lym- 
phokine  growth  factor,  B  cell  growth  factor (BCGF)  (2).  Recent studies  have 
revealed  a  great  deal  about  the  biochemistry and  immunobiology of BCGF, 
including some of its similarities and differences to T  cell growth factor (TCGF; 
IL-2) (3). In fact, putative receptors for TCGF, as determined by the monoclonal 
antibody anti-Tac (4),  have  been  recently shown to be  present on a  subset of 
normal B cells (5). 
Hairy cell leukemia (HCL) is a  chronic B cell leukemia, where the neoplastic 
cells express not only the antigens characteristic of the normal B cell lineage, but 
also the Tac  antigen (6),  suggesting that these  tumor  cells may represent  the 
neoplastic counterpart of the subset of normal B cells that express this putative 
receptor for TCGF. We have studied the proliferative characteristics of in vitro 
HCL cells, which do not spontaneously grow in  cell  culture,  when stimulated 
with  partially purified  BCGF and  with  cloned TCGF  (IL-2),  to  ascertain  the 
possible role of growth factors in the proliferation of these neoplastic B cells. 
Materials and Methods 
Tumor Cells.  HCL cells were obtained from untreated patients with the leukemic form 
of the  disease (white blood cells,  >20,000/mm s) after leukapheresis or venipuncture. 
Peripheral blood mononuclear cells (PBMC)  from these patient samples  were obtained 
after FicolI-Hypaque (F/H) density gradient centrifugation. The PBMC were then rosetted 
overnight at 4 °C with neuraminidaseotreated sheep red blood cells (En). The E,-negative 
cell population, which contained virtually all HCL cells by morphologic criteria in these 
leukemic patients, was obtained by F/H centrifugation of the rosetted cell population 
followed by adherent cell depletion on plastic petri dishes. 
Immunophenotyping  of HCL  Cells.  The  HCL cell  populations  were  microscopically 
examined for the morphologic characteristics of HCL cells on Giemsa-stained smears. 
Tartrate-resistant acid phosphatase (TRAP) cytochemical staining (7) was also performed. 
The HCL cell populations were then pherrotyped by indirect immun0fluorescence for a 
variety of cell membrane markers characteristic of HCL cells, including slg light chain 
monoclonality, the monoclonal antibodies (mAb) B1 (pan B; a gift from Dr. L. Nadler) as 
well as the HCL-associated mAb HC2 (8) (courtesy of Dr.  D.  Posnett) Leu-14/M5 (9) 
(Becton, Dickinson & Co., Mountain View,  CA).  T11  (Ortho Pharmaceutical, Raritan, 
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N  J) was used for identifying T  cells.  The Tac mAb was a  gift from Dr. T. Waldmann, 
National Institutes of Health. 
In  Vitro Proliferation  Studies  on HCL Cells.  Purified populations of HCL cells  were 
cultured in microtiter plates at 1 ×  105 cells/well. Cell viability was >95% by trypan blue 
exclusion after the initial isolation protocol. Growth factor preparations were added  to 
the wells at multiple dilutions. Cultures were incubated for 72 h at 37°C in 5% CO2; 0.5 
~Ci [~H]thymidine [3H]TdR (6 Ci/mmol; New England Nuclear, Boston, MA) was added 
24 h before harvest. 
Growth Factor Preparations.  Human BCGF (12-14 kD) free of TCGF was prepared 
essentially as described. 1 Briefly, 48-h  lectin  (0.08%  PHA-P;  Difco  Laboratories, Inc., 
Detroit,  MI)-stimulated,  pooled  peripheral  blood  T  lymphocytes,  in  the  presence  of 
monocytes (20:1  T  cell/monocyte ratio),  were used for the production of conditioned 
medium.  This  material  was  concentrated  20-fold  using  a  Pellicon  (Millipore  Corp., 
Bedford, MA) concentrator with a  10  kD membrane. A  diaflltered sample was loaded 
and fractionated on a DEAL Sepharose column as described (10). The samples containing 
both TCGF and BCGF were concentrated and applied to a hydroxylapatite column in the 
presence of 10  mM  sodium  phosphate buffer.  The flow-through and  bound  fractions 
from the hydroxylapatite elution were collected and assayed for growth factor activity. 
BCGF activity was found solely in the flow-through fractions, as tested on both anti-~- 
activated B cells and long-term cultured B cell lines. These same fractions were essentially 
devoid of TCGF activity (<5% pre-column activity) as tested on long-term cultured T cell 
lines. The TCGF activity resided in the hydroxylapatite-bound proteins. The BCGF found 
in  the  hydroxylapatite flow-through fractions was  used  for the experiments described 
herein. BCGF activity was selectively enriched ~50-fold after DEAE chromatography and 
further enriched >100-fold after hydroxylapatite chromatography. BCGF was added to 
culture wells in unit (U) amounts determined on long-term cultured B cells as previously 
described (11).  The TCGF used was purified, cloned material kindly provided by Cetus 
Corp., Emeryville, CA (lot No. LP222 endotoxin, 0.06 ng/2.4 x  106 U). TCGF was added 
to the culture wells in unit amounts as previously described (12). 
Cell Culture Studies.  HCL cells were plated in tissue culture macrowells at 0.5 x  10  6 
cells/ml. The cells were grown in RPMI  1640 medium in the presence of 20% fetal calf 
serum (FCS) with or without the addition of 10% vol/vol (18 U) partially purified BCGF. 
The culture wells were fed at 3-4-d intervals with fresh media and 10% (vol/vol) partially 
purified BCGF. At varying intervals the growth factor was deleted when the culture wells 
were fed to evaluate growth factor dependence.  Cell counts and viability by trypan blue 
dye exclusion were performed at regular intervals, as was the cell surface phenotype. 
Results 
Phenotypic  Characterization  of HCL  Cells.  Leukemic  HCL  cells  from  either 
leukapheresis or venipuncture were obtained from untreated patients and were 
assayed  for  cell  surface  markers,  Table  I  shows  that  the  HCL  cells,  which 
resembled hairy cells,  morphologically and  cytochemically (TRAP+),  were also 
phenotypically  consistent  with  this  diagnosis  in  terms  of standard  cell  surface 
markers  for  B  lymphocytes,  including  sIg,  monoclonal  light  chain  type,  and 
expression of the pan B  cell surface antigen,  B1.  Phenotypic markers for HCL- 
associated antigens such as HC2, coexpression of Leu-14/M5, and Tac were also 
positive on the HCL cells (see Table I  for percentage distribution).  It should be 
noted that, of the hairy cell populations examined, all but one HCL population 
was Tac antigen positive. 
Response  of HCL  Cells  to B  Cell  Growth Factor.  Freshly  prepared  HCL  cells 
Mehta, S., D. Conrad, R. Sandler, J. Morgan, R. Montagna, and A. Maizel. Purification of human 
BCGF: 12 kD. Submitted for publication. FORD  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE  I 
Immunologic Markers on Hairy Cell Leukemia Cells 
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Patient No.*  slg*  ~/X  BI  Leu-14/M5 !  HC2  Tac  T11 
1  94  93/2  86  91  87  73  3 
2  59  60/1  38  59  ND  1.0  2 
3  96  98/1  92  93  90  81  2 
4  88  80/3  95  90  90  85  2 
5  89  90/2  83  78  88  75  3 
6  97  94/3  75  92  82  78  2 
7  92  90]3  88  91  81  87  3 
* HCL cells from untreated patients were phenotyped directly after double E. rosetting, and adherence to plastic. 
The  HCL population was morphologically consistent with HCL on Giemsa-stained preparations and contained 
>90 TRAP  + cells on cytospin preparations. 
* Cell surface markers were determined using either direct or indirect immunofluorescence with polyclonal (sIg, 
~/X)  or  monoclonal antibody  reagents.  At  least 300  cells were counted and  the  number  shown reflects the 
percentage of positive staining cells. 
t Double staining cells with Leu-14-FITC and Leu-MS-phycoerythrin (B'ecton, Dickinson & Co.). 
were washed  three  times  in  RPMI  1640  medium  and  subsequently plated  in 
microtiter  plates  at  1  x  105  cells/well  in  RPMI  1640  and  5%  FCS.  Partially 
purified BCGF (free of TCGF activity) was added to the wells in multiple dilutions 
(Fig.  1 A). TdR incorporation  demonstrated that six of the seven HCL popula- 
tions responded to BCGF whereas only background [3H]TdR incorporation was 
observed in these control cultures without the growth factor. As noted, only one 
patient cell population failed to respond to the BCGF growth factor preparation. 
Response  of  HCL Cells to Cloned TCGF.  Since the majority of HCL cells tested 
have been shown to be Tac antigen  positive,  it was of interest to determine  if 
human  TCGF could also stimulate proliferation  in  HCL cells. To explore this 
possibility, we performed parallel proliferative studies, in which HCL cells were 
cultured with multiple dilutions of purified, cloned human IL-2 (TCGF). In Fig. 
1 B, it can be seen that the cloned TCGF resulted in only minimal stimulation of 
[~H]TdR incorporation  in two of seven patients.  The one patient who failed to 
react to BCGF also failed to respond to exogenous TCGF. 
HCL Cell  Growth  In Vitro.  The observed proliferative response of the  HCL 
cells to  BCGF suggested  that  the  growth  factor might  be able to mediate  the 
establishment of growth factor-dependent cell lines in vitro. To test this predic- 
tion, we plated fresh HCL cells in vitro in the presence of BCGF. Fig. 2 shows 
that  sustained  HCL growth  could  be obtained  in  the  presence  of BCGF,  but 
ceased when the growth factor was deleted. The phenotype of these HCL cells 
remained essentially constant throughout the duration of these experiments (see 
Fig. 2 legend). The cell population shown in Fig. 2 was also tested for Epstein- 
Barr nuclear antigen (EBNA) by immunofluorescence and found to be negative. 
Of the  seven  hairy  cell  populations  tested  for  long-term  growth,  all  but  one 
demonstrated in vitro proliferation for at least 30 d  in response to BCGF, with 
four of the seven developing into essentially continuous (>60 d) growth factor- 
dependent  lines.  In  a  further  attempt  to  determine  the  efficacy of TCGF  in 
mediating an HCL proliferative response, HCL cells that had been in culture for 
at least  10 d in the presence of BCGF were washed free of the factor and refed 
with fresh medium, serum, and  1-10 U  of recombinant IL-2. These cell popu- 
lations failed to continue to proliferate, and could not be maintained in vitro on 
recombinant IL-2. 1096  FORD  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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FIGURE  1.  Growth factor-mediated cell proliferation studies performed on seven untreated 
HCL patients leukemic cells.  Microwell HCL cultures (1 X 105 cells/well) were incubated with 
multiple dilutions of partially purified natural product BCGF (A) or recombinant I L-2 (B) for 
72 h, and labeled with 0.5 Ci of [SH]TdR for the final 24 h of the culture period. Data shown 
represents the means of triplicate cultures.  Negative control cultures without gTowth factor 
yielded < 1,000 cpm. Positive control assays using cloned IL-2 on long-term T cell lines yielded: 
0  U, 512 cpm;  1 U, 2,143;  5  U, 7,785;  10  U,  12,740;  50  U,  18,470;  100  U, 24,280  cpm. 
Symbols correspond to individual patients. 
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FIGURE 2.  HCL cells with the phenotype of B1 Tac HC2  + were set up at a density of 0.5 x 
l0  s cells/well. The cells were plated in RPMI, 20% FCS, and 18 U (10% vol/vol) of partially 
purified BCGF per well in 2-ml macrowell cultures. The cultures were counted at 4-d intervals 
adjusted to the original cell density and either refed with BCGF or media and  FCS alone. 
After 30  d  in  vitro, cells from  representative  wells were assayed  for cell surface markers. 
>80% of the viable cells maintained the original phenotype, while Tac and HC2 was absent 
on ~10% of the viable cells.  (i-I) Viable HCL cells cultured with BCGF; (&) viable HCL ceils 
cultured in RPMI and FCS alone. 
Discussion 
The control of normal  human  B cell proliferation  appears to be primarily  a 
function of B cell acquisition of a receptor for BCGF and the ensuing mitogenic 
response to the growth factor. Recently (5), however, a number of investigators 
have reported that a  subset of normal B cells possess the Tac antigen, and that FORD ET  AL.  BRIEF  DEFINITIVE REPORT  1097 
the antigen-positive B cells apparently respond to cloned IL-2 in vitro. The role 
of this apparent second growth factor in human B cell ontogeny is presently an 
intriguing enigma, but may represent a clue to the nature of B cell heterogeneity 
in man. The presence of the Tac antigen on a rather rare type of human B cell 
neoplasm (HCL) may indicate that the disease represents a monoclonal expansion 
of the  normal  subset of B  cells  expressing  the  Tac  antigen.  It  is  interesting, 
however, that the neoplastic cells retain the functional capacity to respond to the 
lineage-specific  growth  factor  (BCGF),  without  anti-#  (Ig)  or  Sac  activation, 
suggesting that  the  BCGF receptor is constitutively expressed.  However, HCL 
cells appear to be only marginally responsive to TCGF, which suggests that the 
Tac antigen, while expressed, may be functionally inactive. Our inability to grow 
HCL cells in cloned IL-2 supports the contention  that the Tac antigen  on the 
tumor cells may be defective, inert, or, possibly, that it is not in fact intrinsically 
associated with the actual receptor for TCGF. Studies by Robb et al. (15) showed 
that the Tac antigen on HCL cells was associated with low affinity IL-2-binding 
sites,  which  they concluded  were  not  involved directly  in  normal  physiologic 
responses to the growth factor. Recent studies by Smith and Cantrell (13), which 
cast some doubt on the Tac antigen  as the putative TCGF receptor, provide a 
possible explanation  for the lack of proliferative activity exhibited by recombi- 
nant  IL-2 on  HCL cells in vitro.  If the Tac antigen  simply represents a  differ- 
entiation antigen that is possibly proximal to the actual TCGF receptor and can 
sterically hinder the interaction  of the growth factor with its receptor, it would 
not  be expected  to  play a  significant  role  in  the  proliferative  capacity of the 
neoplastic cell. If this is the case, the finding of the Tac antigen on HCL may be 
analogous  to  the  finding  of the  T  ceil-associated  antigen  T  101  (Leu-1)  on 
chronic lymphocytic leukemia (CLL) cells of B lineage (14). The finding that the 
lineage-specific  growth  factor,  BCGF,  can  stimulate  growth  in  neoplastically 
transformed  B  cells  such  as  HCL,  which  do  not  grow  spontaneously  in  the 
presence  of autologous or  heterologous  human  serum,  shows that  the  tumor 
cells not only maintain lineage fidelity, but also functional similarities,  with their 
normal  B  cell  counterparts.  This  may  be  of considerable  significance  in  our 
understanding of the immunobiology of the tumor cells. 
Summary 
Leukemic B  cells from seven patients  with hairy cell leukemia (HCL), six of 
which  contained  the  Tac  antigen,  were  assayed  in  vitro  for  growth  factor- 
mediated cell proliferation.  The  HCL cells showed typical phenotypic profiles 
by monoclonal  antibody analysis.  The  tumor cells, which  do not grow sponta- 
neously in  vitro,  were  found to  proliferate  in  all  but  one case in  response  to 
partially purified B cell growth factor (BCGF) without anti-t~  or Sac activation. 
Recombinant  interleukin  2  however produced  only a  marginal  response  and 
could not support leukemic cell growth in vitro. BCGF, however, did stimulate 
in  vitro  cell  growth  and  supported  the  establishment  of continous  (>60  d  in 
vitro) in four of the seven HCL cases. 
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